Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice

Prostate

Volumn 72, Issue 5, 2012, Pages 533-541

  Naiki, Taku ^a   Asamoto, Makoto ^a   Toyoda Hokaiwado, Naomi ^a   Naiki Ito, Aya ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a   Takahashi, Satoru ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

cell line; Gst pi; metastasis; prostate cancer; rats

Indexed keywords

ANDROGEN; GLUTATHIONE TRANSFERASE P1; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANDROGENS; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLUTATHIONE S-TRANSFERASE PI; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84857505343     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21455     Document Type: Article

References (27)

1. Gronberg H,. Prostate cancer epidemiology. Lancet 2003; 361 (9360): 859-864.
2. Huggins C,. Endocrine-induced regression of cancers. Cancer Res 1967; 27 (11): 1925-1930.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
4. Schurko B, Oh WK,. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008; 5 (9): 506-507.
5. Oh WK, Kantoff PW,. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999; 26 (5 Suppl 17): 49-54.
6. Shirai T,. Significance of chemoprevention for prostate cancer development: Experimental in vivo approaches to chemoprevention. Pathol Int 2008; 58 (1): 1-16.
7. Shirai T, Takahashi S, Cui L, Futakuchi M, Kato K, Tamano S, Imaida K,. Experimental prostate carcinogenesisRodent models. Mutat Res 2000; 462 (2-3): 219-226.
8. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, Shirai T,. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001; 61 (12): 4693-4700.
9. Said MM, Hokaiwado N, Tang M, Ogawa K, Suzuki S, Ghanem HM, Esmat AY, Asamoto M, Refaie FM, Shirai T,. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist. Cancer Sci 2006; 97 (6): 459-467.
10. Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K, Shirai T,. Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 2007; 98 (4): 471-477.
11. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T,. Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis 2008; 29 (6): 1134-1138.
12. Nelson WG, De Marzo AM, DeWeese TL,. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 2001; 57 (4 Suppl 1): 39-45.
13. Pathak S, Singh R, Verschoyle RD, Greaves P, Farmer PB, Steward WP, Mellon JK, Gescher AJ, Sharma RA,. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett 2008; 261 (1): 74-83.
14. Miyake H, Hara I, Kamidono S, Eto H,. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol 2004; 171 (4): 1533-1536.
15. Finkel T, Holbrook NJ,. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408 (6809): 239-247.
16. Nose K,. Role of reactive oxygen species in the regulation of physiological functions. Biol Pharm Bull 2000; 23 (8): 897-903.
17. Sauer H, Wartenberg M, Hescheler J,. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001; 11 (4): 173-186.
18. Feig DI, Reid TM, Loeb LA,. Reactive oxygen species in tumorigenesis. Cancer Res 1994; 54 (7 Suppl): 1890s-1894s.
19. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE,. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006; 59 (1): 10-16.
20. Chomyn A, Attardi G,. MtDNA mutations in aging and apoptosis. Biochem Biophys Res Commun 2003; 304 (3): 519-529.
21. Ripple MO, Henry WF, Rago RP, Wilding G,. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997; 89 (1): 40-48.
22. Singh AS, Figg WD,. In vivo models of prostate cancer metastasis to bone. J Urol 2005; 174 (3): 820-826.
23. Finkel T,. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15 (2): 247-254.
24. Kohen R, Nyska A,. Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30 (6): 620-650.
25. Oberley LW, Buettner GR,. Role of superoxide dismutase in cancer: A review. Cancer Res 1979; 39 (4): 1141-1149.
26. Morel F, Fardel O, Meyer DJ, Langouet S, Gilmore KS, Meunier B, Tu CP, Kensler TW, Ketterer B, Guillouzo A,. Preferential increase of glutathione S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res 1993; 53 (2): 231-234.
27. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S,. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62 (18): 5196-5203.